Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
0.5256
-0.0002 (-0.04%)
Dec 5, 2025, 4:00 PM EST - Market closed
Century Therapeutics Stock Forecast
IPSC's stock price has decreased by -63.5% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Century Therapeutics stock ranges from a low of $2.00 to a high of $6.00. The average analyst price target of $3.00 forecasts a 470.78% increase in the stock price over the next year.
Price Target: $3.00 (+470.78%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Century Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $7 → $2 | Buy → Hold | Downgrades | $7 → $2 | +280.52% | Nov 17, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $7 → $6 | Strong Buy | Maintains | $7 → $6 | +1,041.55% | May 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $2 | Strong Buy | Maintains | $5 → $2 | +280.52% | Apr 3, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 → $7 | Strong Buy | Maintains | $11 → $7 | +1,231.81% | Mar 24, 2025 |
Financial Forecast
Revenue This Year
111.36M
from 6.59M
Increased by 1,590.09%
Revenue Next Year
n/a
from 111.36M
EPS This Year
-0.14
from -1.61
EPS Next Year
-0.88
from -0.14
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 114.7M | n/a | ||||
| Avg | 111.4M | n/a | ||||
| Low | 107.0M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1,640.2% | - | ||||
| Avg | 1,590.1% | - | ||||
| Low | 1,523.6% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.14 | -0.86 | |
| Avg | -0.14 | -0.88 | |
| Low | -0.14 | -0.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.